Literature DB >> 27051495

Intravitreal Bevacizumab for Management of Choroidal Osteoma without Choroidal Neovascularization.

Farhad Fazel Najafabadi1, Seyyed Moien Hendimarjan2, Yasaman Zarrin2, Mohammadreza Fazel Najafabadi2.   

Abstract

To report a patient with juxtapapillary choroidal osteoma (CO) with serous retinal detachment (SRD) not associated with choroidal neovascularization (CNV) who was successfully treated with a single intravitreal injection of bevacizumab. A 20-year-old woman presented with decreased vision in her right eye. Ultrasonography, fundus autofluorescence, fluorescein angiography (FA) and optical coherence tomography (OCT) were performed. She was diagnosed with juxtapapillary CO with SRD in the absence of CNV. The treatment involved a single intravitreal injection of bevacizumab. Visual acuity (VA) was 20/100 pre-injection which was dramatically improved to 20/20 one week after the injection without any additional treatment. Fundus examination and OCT one week after the injection revealed complete absorption of the subretinal fluid (SRF) in the macula. Eighteen months after the injection, vision remained stable and she did not show re-accumulation of SRF in her right eye. Intravitreal injection of bevacizumab may be effective in managing CO associated with SRF without CNV.

Entities:  

Keywords:  Choroidal Osteoma; Intravitreal Bevacizumab; Serous Retinal Detachment

Year:  2015        PMID: 27051495      PMCID: PMC4795400          DOI: 10.4103/2008-322X.176905

Source DB:  PubMed          Journal:  J Ophthalmic Vis Res        ISSN: 2008-322X


  17 in total

1.  Intravitreal bevacizumab in the management of subretinal fluid associated with choroidal osteoma.

Authors:  Ji Hun Song; Jeong Hun Bae; Mi In Rho; Sung Chul Lee
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

2.  Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia.

Authors:  Q D Nguyen; S Shah; S Tatlipinar; D V Do; E V Anden; P A Campochiaro
Journal:  Br J Ophthalmol       Date:  2005-10       Impact factor: 4.638

3.  Intravitreal bevacizumab for choroidal neovascularization secondary to choroidal osteoma.

Authors:  Won Kyung Song; Hyoung Jun Koh; Oh Woong Kwon; Suk Ho Byeon; Sung Chul Lee
Journal:  Acta Ophthalmol       Date:  2009-02       Impact factor: 3.761

4.  Intravitreal ranibizumab in a patient with choroidal neovascularization secondary to choroidal osteoma.

Authors:  M-h Song; Y-j Roh
Journal:  Eye (Lond)       Date:  2008-10-24       Impact factor: 3.775

Review 5.  Choroidal osteoma.

Authors:  C L Shields; J A Shields; J J Augsburger
Journal:  Surv Ophthalmol       Date:  1988 Jul-Aug       Impact factor: 6.048

6.  Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.

Authors:  Rogério A Costa; Rodrigo Jorge; Daniela Calucci; José A Cardillo; Luiz A S Melo; Ingrid U Scott
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-10       Impact factor: 4.799

7.  Choroidal osteoma: observations from a community setting.

Authors:  David J Browning
Journal:  Ophthalmology       Date:  2003-07       Impact factor: 12.079

8.  Choroidal Osteoma.

Authors:  J D Gass; R K Guerry; R L Jack; G Harris
Journal:  Arch Ophthalmol       Date:  1978-03

Review 9.  Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.

Authors:  Helen Kourlas; Paris Abrams
Journal:  Clin Ther       Date:  2007-09       Impact factor: 3.393

10.  Dramatic response of choroidal neovascularization associated with choroidal osteoma to the intravitreal injection of bevacizumab (Avastin).

Authors:  Hamid Ahmadieh; Nasser Vafi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-07-25       Impact factor: 3.117

View more
  1 in total

1.  Choroidal osteoma: the varied response of subretinal fluid to anti-VEGF agents.

Authors:  Subina Narang; Meenakshi Sindhu; Khushboo Sheoran; Ravinder Kaur
Journal:  BMJ Case Rep       Date:  2020-05-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.